Benitec Biopharma Inc.
BNTC
$12.77
$0.191.47%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | 100.00% | 97.14% | 98.11% |
| Gross Profit | -- | -- | -100.00% | -98.19% | -98.90% |
| SG&A Expenses | 261.85% | 235.28% | 89.56% | 56.65% | 27.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 104.30% | 85.70% | 40.18% | 10.74% | 9.57% |
| Operating Income | -104.30% | -85.70% | -40.22% | -11.05% | -9.97% |
| Income Before Tax | -100.53% | -74.32% | -22.12% | 1.81% | -2.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -100.53% | -74.32% | -22.12% | 1.81% | -2.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -100.53% | -74.32% | -22.12% | 1.81% | -2.12% |
| EBIT | -104.30% | -85.70% | -40.22% | -11.05% | -9.97% |
| EBITDA | -104.91% | -86.13% | -40.40% | -11.10% | -10.13% |
| EPS Basic | 63.43% | 81.17% | 89.26% | 91.68% | 72.78% |
| Normalized Basic EPS | 63.42% | 80.23% | 88.90% | 91.46% | 72.10% |
| EPS Diluted | 63.43% | 81.17% | 89.26% | 91.68% | 72.78% |
| Normalized Diluted EPS | 63.42% | 80.23% | 88.90% | 91.46% | 72.10% |
| Average Basic Shares Outstanding | 92.24% | 165.58% | 363.85% | 1,072.28% | 954.82% |
| Average Diluted Shares Outstanding | 92.24% | 165.58% | 363.85% | 1,072.28% | 954.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |